AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23101257
Drug: Combined antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVE COMBINATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined antihypertensive therapy (long-acting verapamil combined with slow-release indapamide)
Trial: 23101257
Drug: Combined antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVE COMBINATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined antihypertensive therapy (long-acting verapamil combined with enalapril)
Trial: 19446147
Drug: Standard-dose prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-dose prednisone regimen (1 mg/kg daily)
Trial: 19446147
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) combined with lower prednisone dose (0.5 mg/kg daily)
Trial: 16447665
Drug: TCM and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCM and western drugs (Control)
Trial: 6945060
Drug: Vincristine (VCR)
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vincristine (VCR) 2 mg/m2 on day 1 and Cyclophosphamide (CP) 450 mg/m2 on days 2 and 3 (two-drug regimen)
Trial: 6945060
Drug: Vincristine (VCR)
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vincristine (VCR) 2 mg/m2 on day 1, Cyclophosphamide (CP) 450 mg/m2 on days 2 and 3, and BCNU 50 mg on days 2 and 3 (three-drug regimen)
Trial: 31580695
Drug: Combination Therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination Therapy (IC + Dry Cupping)
Trial: 28260863
Drug: Glimepiride in
RxNorm normalized name: Product containing glimepiride in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride in combination with rosuvastatin
Trial: 28260863
Drug: Rosuvastatin in
RxNorm normalized name: Product containing rosuvastatin in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin in combination with glimepiride
Trial: 23676106
Drug: Oral metformin
RxNorm normalized name: metformin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral metformin (250 mg three times daily in the first week, followed by 500 mg three times daily thereafter)
Trial: 20972351
Drug: Atorvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (20 mg) for 6 months in patients with high baseline LDL-C (≥ 100 mg/dL)
Trial: 20972351
Drug: Atorvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (20 mg) for 6 months in patients with low baseline LDL-C (< 100 mg/dL)
Trial: 20361714
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g of cardamom powder administered in two divided doses for 12 weeks
Trial: 11282259
Drug: Memantine (0.16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine (0.16 mg/kg)
Trial: 7699618
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment strategies
Trial: 3129807
Drug: DDAVP 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDAVP 0.4 microgram kg‐1 intravenous (i.v.)
Trial: 3129807
Drug: DDAVP 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDAVP 0.4 microgram kg‐1 subcutaneous (s.c.)
Trial: 28993287
Drug: Certified diabetes
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Certified diabetes educators (CDEs) implementing standardized protocols to intensify treatment
Trial: 26434249
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of APE (71.64-72.36 mg/day)
Trial: 26434249
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of APE (119.64-120.36 mg/day)
Trial: 26434249
Drug: Gemfibrozil (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemfibrozil (300 mg/day)
Trial: 23552120
Drug: Spironolactone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (25 mg thrice weekly after dialysis for 4 months)
Trial: 18218298
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (dexibuprofen 400 mg by Emcure Pharmaceuticals)
Trial: 18218298
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (dexibuprofen 400 mg by Genus Pharmaceuticals)
Trial: 16272449
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg intravenous hydrocortisone every 6 h
Trial: 14620923
Drug: Candesartan (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (8 mg daily)
Trial: 12808270
Drug: Candesartan plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan plus probucol (500 mg daily)
Trial: 1681355
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (atenolol plus isosorbide mononitrate and nifedipine)
Trial: 6307330
Drug: Delta-9-tetrahydrocannabinol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delta-9-tetrahydrocannabinol (0.5 mg i.v.)
Trial: 6307330
Drug: Delta-9-tetrahydrocannabinol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delta-9-tetrahydrocannabinol (1 mg i.v.)
Trial: 28644680
Drug: SCORS‐G scales
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCORS‐G scales
Trial: 28644680
Drug: SCORS‐G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCORS‐G
Trial: 20554708
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid 5 mg annually
Trial: 18936231
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A (240 mg)
Trial: 11310904
Drug: Non-EDTA sedative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-EDTA sedative agents
Trial: 8612407
Drug: Reconstituted high-density
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reconstituted high-density lipoprotein preparation (2 mg/mL)
Trial: 1348620
Drug: Vecuronium 0.015
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.015 mg/kg (priming) followed by 0.285 mg/kg
Trial: 1348620
Drug: Vecuronium 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.3 mg/kg (single dose)
Trial: 1348620
Drug: Vecuronium 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.3 mg/kg (both groups)
Trial: 1348620
Drug: Edrophonium 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium 0.75 mg/kg for reversal
Trial: 20415689
Drug: Biphasic insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biphasic insulin aspart 50 (BIAsp 50)
Trial: 20415689
Drug: Biphasic insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biphasic insulin aspart 70 (BIAsp 70)
Trial: 19066382
Drug: Dexamethasone 0.05
RxNorm normalized name: dexamethasone 0.05 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.05 mg/kg
Trial: 16029524
Drug: Early conservative
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early conservative treatment
Trial: 10647168
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy treatment based on classification
Trial: 1341133
Drug: 4 ml
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml of a mixture including 3 ml of 0.5% bupivacaine, 1 ml fentanyl in 1 ml of 10% dextrose solution (Group II)
Trial: 1341133
Drug: 4 ml
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml of a mixture including 3 ml of 0.5% bupivacaine, 0.15 mg clonidine (Group IV)
Trial: 1341133
Drug: 4 ml
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml of 0.5% bupivacaine at 5 degrees C (Group VI)
Trial: 1341133
Drug: 4 ml
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml of 0.5% bupivacaine at 27 degrees C (Group I)
Trial: 1341133
Drug: 4 ml
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml of 0.5% bupivacaine at 20 degrees C (Group V)
Trial: 1341133
Drug: 4 ml
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml of a mixture including 3 ml of 0.5% bupivacaine, 0.20 mg adrenaline (Group III)
Trial: 22357252
Drug: Paclitaxel (175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (175 mg/m²) plus carboplatin (AUC5) followed by radiation (50.4 Gy) (arm-A)
Trial: 22357252
Drug: Simultaneous radiochemotherapy
RxNorm normalized name: Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways
DrugBank: Acazicolcept (DB18410)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous radiochemotherapy with cisplatin (40 mg/m²/week) (arm-B)
Trial: 17397698
Drug: Dextromethorphan (DM)
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dextromethorphan (DM) plus slow-release morphine
Trial: 17397698
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus slow-release morphine
Trial: 11747767
Drug: Domestic anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Domestic anastrozole tablet (1 mg)
Trial: 11747767
Drug: Imported anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Imported anastrozole tablet (1 mg)
Trial: 8422222
Drug: Alprazolam (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (mean daily dose of 5.7 mg)
Trial: 8422222
Drug: Imipramine hydrochloride
RxNorm normalized name: Imipramine Hydrochloride
DrugBank: Imipramine (DB00458)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Imipramine hydrochloride (175 mg/d)
Trial: 3312502
Drug: Labetalol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (100 to 800 mg BID)
Trial: 3312502
Drug: Labetalol +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol + Diuretic
Trial: 3312502
Drug: Propranolol +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol + Diuretic
Trial: 26153271
Drug: MPCs (rexlemestrocel-L)
RxNorm normalized name: Rexlemestrocel-L
DrugBank: Rexlemestrocel-L (DB17606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPCs (rexlemestrocel-L) 0.3 × 10(6)/kg, n = 15
Trial: 26153271
Drug: MPCs (rexlemestrocel-L)
RxNorm normalized name: Rexlemestrocel-L
DrugBank: Rexlemestrocel-L (DB17606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPCs (rexlemestrocel-L) 1.0 × 10(6)/kg, n = 15
Trial: 26153271
Drug: MPCs (rexlemestrocel-L)
RxNorm normalized name: Rexlemestrocel-L
DrugBank: Rexlemestrocel-L (DB17606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPCs (rexlemestrocel-L) 2.0 × 10(6)/kg, n = 15
Trial: 21823276
Drug: Compound Danshen
RxNorm normalized name: DANSHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Danshen dripping pill (medicine group)
Trial: 11986453
Drug: Zinc syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc syrup
Trial: 11986453
Drug: Zinc syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc syrup and vitamin A
Trial: 11986453
Drug: Zinc syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc syrup (caretaker administered)
Trial: 7666102
Drug: Dexamethasone plus
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone plus granisetron (dexamethasone 8 mg IV + granisetron 3 mg IV)
Trial: 7666102
Drug: Granisetron alone
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron alone (3 mg IV)
Trial: 7666102
Drug: Dexamethasone alone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone alone (8 mg IV)
Trial: 2548660
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate (600 mg in 3 divided doses p.o.)
Trial: 28038376
Drug: Intramuscular fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular fat fractions
Trial: 22046702
Drug: Intranasal ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal ketamine (K)
Trial: 22046702
Drug: Intranasal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal midazolam (M)
Trial: 22046702
Drug: Intranasal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal midazolam and ketamine combination (MK)
Trial: 15677433
Drug: Conventional antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antipsychotics or risperidone
Trial: 8198905
Drug: 1.5% lignocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% lignocaine 15 ml with adrenaline infiltrated into the proposed wound line 3 min before incision
Trial: 8198905
Drug: Lignocaine 15
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine 15 ml with adrenaline infiltrated into the wound on closure
Trial: 31420064
Drug: Dexamethasone (intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (intramuscular regimen)
Trial: 24574052
Drug: Levofloxacin (LFX)
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin (LFX) 500 mg, once daily (o.d.)
Trial: 24574052
Drug: Placebo, once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, once daily (o.d.)
Trial: 21383263
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (cognitive behavior therapy plus switch to a different antidepressant medication)
Trial: 7530706
Drug: Inhaled substance
RxNorm normalized name: Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled substance P (SP) at doses of 0.25-8 mg/ml
Trial: 30309257
Drug: 12-month maintenance
RxNorm normalized name: cenobamate
DrugBank: Cenobamate (DB06119)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 12-month maintenance treatment
Trial: 21434488
Drug: Tramadol/Paracetamol (TP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol/Paracetamol (TP 37.5/325 mg)
Trial: 21434488
Drug: Paracetamol/Codeine (CP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol/Codeine (CP 30/500 mg)
Trial: 19097715
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg raloxifene (RLX)
Trial: 19097715
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg percutaneous 17beta-estradiol associated to 60 mg raloxifene (RLX+E2)
Trial: 12775172
Drug: Access to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Access to the program (treatment group)
Trial: 10990237
Drug: Hydrocortisone (13
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (13 mg/m2 every morning and 3 mg/m2 every afternoon for 12 weeks)
Trial: 8649699
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of vitamin B6
Trial: 3579005
Drug: Orally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered theophylline
Trial: 3579005
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of inhaled salbutamol and orally administered theophylline
Trial: 1348010
Drug: Prednisolone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (20 mg)
Trial: 31962050
Drug: Cervarix and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervarix and Gardasil (HPV vaccines)
Trial: 31255678
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (absent depression)
Trial: 30580340
Drug: Sildenafil 25
RxNorm normalized name: sildenafil 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 25 mg thrice daily
Trial: 30580340
Drug: Optimal medical
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal medical therapy (Control)
Trial: 25952634
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine plus gliclazide modified release combination therapy
Trial: 25952634
Drug: Premixed insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Premixed insulin monotherapy
Trial: 23498848
Drug: SYN1 (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYN1 (0.8 g/dL Orafti®Synergy1) supplemented infant formula
Trial: 16278686
Drug: DHA-rich algae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-rich algae oil (2.14 g of DHA/day)
Trial: 16278686
Drug: Corn oil
RxNorm normalized name: Corn Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corn oil (6 g)
Trial: 11519638
Drug: Chronic nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic nicotine treatment
Trial: 11519638
Drug: Acute nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acute nicotine treatment
Trial: 7965876
Drug: Bupivacaine 0.5%
RxNorm normalized name: BUPivacaine 0.5% injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.5% 2-6 ml/h infusion through a catheter placed in the sciatic or posterior tibial nerve sheath
Trial: 7965876
Drug: Bupivacaine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine treatment
Trial: 3662562
Drug: Betamethasone dipropionate
RxNorm normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone dipropionate in optimized vehicle (ointment)
Trial: 17211115
Drug: Essential oil
RxNorm normalized name: Essential oil
DrugBank: Rosemary oil (DB14689)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Essential oil group (aromatherapy with lavender, ylangylang, and bergamot, once daily for 4 weeks)
Trial: 12845429
Drug: 30 mmol
RxNorm normalized name: Dextrose/Potassium Phosphate 5%-30 MMOLE Intravenous Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mmol potassium phosphate in 50 ml saline over 2 h (Group 1)
Trial: 12845429
Drug: 30 mmol
RxNorm normalized name: Dextrose/Potassium Phosphate 5%-30 MMOLE Intravenous Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mmol potassium phosphate in 100 ml saline over 4 h (Group 2)
Trial: 12845429
Drug: 45 mmol
RxNorm normalized name: dibasic potassium phosphate 45 MMOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mmol potassium phosphate in 100 ml saline over 3 h (Group 3)
Trial: 12845429
Drug: 45 mmol
RxNorm normalized name: dibasic potassium phosphate 45 MMOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mmol potassium phosphate in 100 ml saline over 6 h (Group 4)
Trial: 11282702
Drug: Four-session interpersonal-therapy-oriented
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-session interpersonal-therapy-oriented group intervention
Trial: 11282702
Drug: Treatment-as-usual condition
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual condition
Trial: 9250849
Drug: Phenobarbital (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbital (10 mg/kg body weight, intravenous, followed by maintenance doses until delivery or 34 weeks gestation)
Trial: 9250849
Drug: Placebo (intravenous,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intravenous, followed by maintenance doses until delivery or 34 weeks gestation)
Trial: 28720658
Drug: Ticagrelor (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (180 mg loading dose on day 1 followed by 90 mg twice daily for days 2-90)
Trial: 28720658
Drug: Aspirin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (300 mg on day 1 followed by 100 mg daily for days 2-90)
Trial: 23744427
Drug: High-dose metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose metformin (3 g daily in three divided doses)
Trial: 16420274
Drug: Canine retraction
RxNorm normalized name: CanineAid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canine retraction using 100 g sentalloy springs
Trial: 11117374
Drug: Enalapril (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (10-20 mg) and Verapamil (120-240 mg)
Trial: 9315788
Drug: Regular inhaled
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular inhaled beta-agonist therapy